Возраст домена | 21 год |
Дата окончания | Истек срок регистрации |
PR | 5 |
ИКС | |
Страниц в Google | 136 |
Страниц в Яндексе | 107 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | Нет данных |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
SILLAJEN
SillaJen, pexavec, korea, cancer, oncolytic, office
SillaJen is a privately-held biotechnology company focused on engineering and developing best-in-class oncolytic virus immunotherapeutics. A global leader in oncolytic immunotherapeutics Targeting, Attacking and Eradicating Cancers
UTF-8
49.28 КБ
439
3 894 симв.
3 360 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
indeed.com | 15 | 8 |
0 | 138 | 50 | |
linkedin.com | 11 | 9 |
0 | 25 | 10 | |
socra.org | 9 | 6 |
0 | 797228 | 233043 | |
bbc.co.uk | 9 | 9 |
0 | 98 | 6 | |
monster.com | 8 | 8 |
0 | 2488 | 731 | |
google.com | 8 | 9 |
0 | 1 | 1 | |
postjobfree.com | 7 | 3 |
10 | 70151 | 32345 | |
ehow.com | 7 | 6 |
0 | 9605 | 2654 | |
docsglobal.com | 7 | 6 |
0 | 2356023 | Нет данных | |
wikipedia.org | 7 | 9 |
0 | 5 | 6 | |
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 31 Августа 2012 ) | |
Количество ссылок на сайт | 37 |
Количество доменов, которые ссылаются на сайт | 20 |
Количество найденных анкоров | 10 |
Исходящие (внешние) ссылки домена | 3 |
Количество доменов, на которые ссылается сайт | 3 |
Количество исходящих анкоров | 3 |
Внешние ссылки главной страницы ( 4 ) | |
prnewswire.com/news-releases/sillajen-announces-first-patien... | SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's ... |
prnewswire.com/news-releases/sillajen-and-lees-pharmaceutica... | SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncoly... |
prnewswire.com/news-releases/sillajen-announces-first-patien... | SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab... |
prnewswire.com/news-releases/sillajen-poster-presentation-at... | SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, On... |
Внутренние ссылки главной страницы ( 24 ) | |
# | TOP |
/eng | ENG |
/eng/sub/ceo_message.html | CEO Message |
/eng/sub/company_history.html | Company History |
/eng/sub/management_status.html | Management |
/eng/sub/jennerex.html | Jennerex |
/eng/sub/location_info.html | Contact Us |
/eng/sub/solve_platform.html | SOLVE ® |
/eng/sub/thesis.html | Scientific Publications |
/eng/sub/pipeline_overview.html | Development Pipeline |
/eng/sub/pipeline_pexavec.html | Pexa-Vec is the most advanced product candidate. Pexa-Vec is engineered to selectively infect and replicate in cancer cells by e... |
/eng/sub/pipeline_jx900.html | JX-970 is next generation pipeline. In preclinical studies, JX-970 exerted tumor debulking effect and the same time demonstrated... |
/eng/sub/partnership.html | SillaJen is actively seeking development partners and/or licensing opportunities for all of its assets. |
/eng/sub/notice_list.html | Notice & News |
/eng/sub/sub0505.html | Stock Information 신라젠의 주요 공고문을열람하실 수 있습니다. |
/eng/sub/financial_status.html | Financials 전자공시시스템 보고서를확인하실 수 있습니다. |
/eng/sub/qna.html | IR Inquiries 신라젠에 대해 궁금한모든 것들을 안내해드립니다. |
/eng/sub/subsidiary.html | About SillaJen Biotherapeutics |
/eng/sub/subsidiary_location.html | Contact Us |
/kor | KOR |
/eng/sub/sillajen_wiki.html | Frequently AskedQuestions 자주 묻는 질문들을열람하실 수 있습니다. |
/eng/sub/website_condition.html | Website Terms and Conditions |
/eng/sub/privacy_policy.html | Privacy Policy |
/eng/sub/uncollection_email.html | Unauthorized collection of email |
[Querying whois.verisign-grs.com]
[Redirected to whois.melbourneit.com]
[Querying whois.melbourneit.com]
[whois.melbourneit.com]
Domain Name.......... jennerex.com
Creation Date........ 2002-06-28
Registration Date.... 2002-06-28
Expiry Date.......... 2020-06-28
Organisation Name.... Jennerex
Organisation Address. 444 Laverne
Organisation Address.
Organisation Address.
Organisation Address. Mill Valley
Organisation Address. 94941
Organisation Address. CA
Organisation Address. UNITED STATES
Admin Name........... David Kirn
Admin Address........ 444 Laverne
Admin Address........
Admin Address........
Admin Address. Mill Valley
Admin Address........ 94941
Admin Address........ CA
Admin Address........ UNITED STATES
Admin Email.......... davidhkirn@sbcglobal.net
Admin Phone.......... (415)-388-6016
Admin Fax............
Tech Name............ VERIO VERIO
Tech Address......... 12345 Blue Lake Dr.
Tech Address.........
Tech Address.........
Tech Address......... Boca Raton
Tech Address......... 33431
Tech Address......... FL
Tech Address......... UNITED STATES
Tech Email........... hostmaster@VERIO-HOSTING.COM
Tech Phone........... 888-663-6648
Tech Fax.............
Name Server.......... ns1.ipage.com
Name Server.......... ns2.ipage.com
США - 208.80.152.201
Wikimedia Foundation
Wikimedia Foundation
HTTP/1.1 200 OK
Date: Thu, 12 Sep 2019 19:19:07 GMT
Server: Apache
X-Powered-By: PHP/5.3.3
Set-Cookie: PHPSESSID=mujqpmlrao5dogsd82qptn6ha7; path=/
Expires: Thu, 19 Nov 1981 08:52:00 GMT
Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Pragma: no-cache
P3P: CP="NOI CURa ADMa DEVa TAIa OUR DELa BUS IND PHY ONL UNI COM NAV INT DEM PRE"
Vary: User-Agent,Accept-Encoding
Transfer-Encoding: chunked
Content-Type: text/html; charset=UTF-8
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"